‘Molecular glue’ turns a cancer driver into a built-in kill switch in Stanford Medicine study

Top Story‘Molecular glue’ turns a cancer driver into a built-in kill switch in Stanford Medicine study

Stanford Medicine

Stanford Medicine researchers have developed a molecule that reprograms the cancer-driving protein BCL6 into a trigger for cell death. In preclinical trials, this approach eliminated aggressive B-cell lymphoma tumors in mice within 11 days. The study, published in Cell, was led by Dr. Gerald Crabtree and Dr. Nathanael Gray, in collaboration with MD Anderson Cancer Center.

This breakthrough builds on Stanford’s prior work in re-engineering cancer-causing proteins and suggests potential applications for other cancers and autoimmune diseases. The findings reinforce Stanford’s leadership in high-impact medical research and its ability to attract top-tier academic and industry collaborators.

Investment implication: This is Stanford’s second major oncology milestone in two months, following its antibody localization breakthrough. For you, it signals a strong trajectory in cancer research, with implications for funding opportunities and potential partnerships in translational medicine.